Dr. Singh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2016 - 2019- University of Pennsylvania Health SystemResidency, Internal Medicine, 2013 - 2016
Perelman School of Medicine at the University of PennsylvaniaClass of 2013
Certifications & Licensure
MO State Medical License 2019 - 2026
PA State Medical License 2013 - 2021
CA State Medical License 2015 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors.Ju-Fang Chang, Jack H Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin
Cancer Discovery. 2024-11-01 - 1 citationsRegulatory Considerations for Genome-Edited T-cell Therapies.Julie K Jadlowsky, Ju-Fang Chang, David H Spencer, John M Warrington, Bruce L Levine
Cancer Immunology Research. 2024-09-03 - Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors.Ju-Fang Chang, Nils Wellhausen, Nils W Engel, Jack H Landmann, Caitlin R Hopkins
Cancer Immunology Research. 2024-09-03
Journal Articles
- Genome-Editing Technologies in Adoptive T Cell Immunotherapy for CancerNathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports
Press Mentions
Precise Features of CAR T Cell-Resistant Cancer Have Been IdentifiedFebruary 3rd, 2020
Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients with ALL and LymphomaMarch 1st, 2016
Grant Support
- Decoding 41BB-specific dysfunction programs in cellular immunotherapies for cancerWASHINGTON UNIVERSITY2024–2028
- Decoding 41BB-specific dysfunction programs in cellular immunotherapies for cancerWASHINGTON UNIVERSITY2024–2028
- Mechanisms regulating chimeric antigen receptor T-cell activity in cancerWASHINGTON UNIVERSITY2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
